PL3778647T3 - Przeciwciało specyficznie wiążące się z erbb3 i jego zastosowanie - Google Patents

Przeciwciało specyficznie wiążące się z erbb3 i jego zastosowanie

Info

Publication number
PL3778647T3
PL3778647T3 PL20196712.2T PL20196712T PL3778647T3 PL 3778647 T3 PL3778647 T3 PL 3778647T3 PL 20196712 T PL20196712 T PL 20196712T PL 3778647 T3 PL3778647 T3 PL 3778647T3
Authority
PL
Poland
Prior art keywords
erbb3
specifically binding
antibody specifically
antibody
binding
Prior art date
Application number
PL20196712.2T
Other languages
English (en)
Inventor
Dong Goo Bae
Mi Young Kim
Young Mi Hur
Mi Rim HONG
Original Assignee
Isu Abxis Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59013461&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3778647(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Isu Abxis Co., Ltd. filed Critical Isu Abxis Co., Ltd.
Publication of PL3778647T3 publication Critical patent/PL3778647T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL20196712.2T 2015-12-07 2016-11-02 Przeciwciało specyficznie wiążące się z erbb3 i jego zastosowanie PL3778647T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020150173281A KR101746152B1 (ko) 2015-12-07 2015-12-07 ErbB3에 특이적으로 결합하는 항체 및 그의 용도

Publications (1)

Publication Number Publication Date
PL3778647T3 true PL3778647T3 (pl) 2026-06-01

Family

ID=59013461

Family Applications (2)

Application Number Title Priority Date Filing Date
PL16873228T PL3362480T3 (pl) 2015-12-07 2016-11-02 Przeciwciało specyficznie wiążące się z ERBB3 i jego zastosowanie
PL20196712.2T PL3778647T3 (pl) 2015-12-07 2016-11-02 Przeciwciało specyficznie wiążące się z erbb3 i jego zastosowanie

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL16873228T PL3362480T3 (pl) 2015-12-07 2016-11-02 Przeciwciało specyficznie wiążące się z ERBB3 i jego zastosowanie

Country Status (14)

Country Link
US (1) US10413607B2 (pl)
EP (2) EP3362480B1 (pl)
JP (2) JP6982574B2 (pl)
KR (1) KR101746152B1 (pl)
CN (2) CN107683292B (pl)
AR (1) AR107012A1 (pl)
AU (1) AU2016365506B2 (pl)
CA (1) CA3000835C (pl)
ES (2) ES2891990T3 (pl)
MX (1) MX394911B (pl)
PL (2) PL3362480T3 (pl)
RU (1) RU2707121C9 (pl)
TW (1) TWI615406B (pl)
WO (1) WO2017099362A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020080853A1 (ko) * 2018-10-17 2020-04-23 주식회사 굳티셀 Lrig-1 단백질에 특이적인 결합 분자 및 이의 용도
US12551584B1 (en) 2020-12-07 2026-02-17 Actinium Pharmaceuticals, Inc. Lewis Y radioimmunotherapy for the treatment of cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0173281B1 (ko) 1996-11-30 1999-02-18 양재신 자동차의 램프 각도 조절장치
NZ579644A (en) * 2007-02-16 2012-05-25 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof
JP5639039B2 (ja) * 2008-04-11 2014-12-10 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
CN102282168A (zh) 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
US8895001B2 (en) * 2010-03-11 2014-11-25 Merrimack Pharmaceuticals, Inc. Use of ErbB3 inhibitors in the treatment of triple negative and basal-like breast cancers
KR101764453B1 (ko) * 2010-04-09 2017-08-02 아베오 파마슈티컬즈, 인크. 항-erbb3 항체
ME02637B (me) * 2010-08-20 2017-06-20 Novartis Ag Antitela za receptor 3 faktora rasta epiderma (her3)
WO2012176779A1 (ja) * 2011-06-20 2012-12-27 協和発酵キリン株式会社 抗erbB3抗体
WO2013048883A2 (en) 2011-09-30 2013-04-04 Regeneron Pharmaceuticals, Inc. Anti-erbb3 antibodies and uses thereof
US9273143B2 (en) 2011-09-30 2016-03-01 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
US11305012B2 (en) * 2013-09-24 2022-04-19 Medimmune, Llc Binding molecules specific for HER3 and uses thereof

Also Published As

Publication number Publication date
TW201726742A (zh) 2017-08-01
CN112472804A (zh) 2021-03-12
CA3000835C (en) 2020-06-09
RU2018113269A (ru) 2019-10-18
ES3067074T3 (en) 2026-05-19
AR107012A1 (es) 2018-03-14
PL3362480T3 (pl) 2022-01-03
RU2018113269A3 (pl) 2019-10-18
EP3778647B1 (en) 2026-02-25
TWI615406B (zh) 2018-02-21
JP6982574B2 (ja) 2021-12-17
RU2707121C9 (ru) 2020-06-16
CA3000835A1 (en) 2017-06-15
ES2891990T3 (es) 2022-02-01
WO2017099362A1 (en) 2017-06-15
MX2018004228A (es) 2018-05-15
JP2020117512A (ja) 2020-08-06
CN107683292B (zh) 2021-06-08
JP2018536026A (ja) 2018-12-06
KR101746152B1 (ko) 2017-06-13
MX394911B (es) 2025-03-24
EP3362480B1 (en) 2021-08-04
CN112472804B (zh) 2024-07-23
US20180085455A1 (en) 2018-03-29
CN107683292A (zh) 2018-02-09
AU2016365506A1 (en) 2018-04-12
JP6989645B2 (ja) 2022-01-05
EP3362480A4 (en) 2019-06-05
RU2707121C2 (ru) 2019-11-22
AU2016365506B2 (en) 2019-06-20
EP3362480A1 (en) 2018-08-22
BR112018006900A2 (pt) 2018-10-16
EP3778647A1 (en) 2021-02-17
AU2016365506A9 (en) 2018-11-01
US10413607B2 (en) 2019-09-17